Our evidence for the capacity of G-CSF-mobilized MPP to modulate autoimmunity (type 1 diabetes and EAE) through Foxp3+ Treg expansion and stabilization provides a further argument for their possible benefit during allo-HSCT. This evidence concerns the gene FOXP3 and type 1 diabetes mellitus.